Avalo Therapeutics (AVTX) Capital Expenditures (2016 - 2023)
Avalo Therapeutics posted quarterly Capital Expenditures of $158000.0 for Q1 2023, up 266.32% on a QoQ basis from -$95000.0 in Q4 2022.
Avalo Therapeutics (AVTX) has 8 years of Capital Expenditures data on file, last reported at $158000.0 in Q1 2023.
- For the quarter ending Q1 2023, Capital Expenditures changed N/A year-over-year to $158000.0; the trailing twelve-month figure through Dec 2023 stood at $158000.0 (changed N/A YoY), and the FY2023 full-year result was $158000.0, changed N/A from the prior year.
- Capital Expenditures for Q1 2023 stood at $158000.0, up from -$95000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $165969.0 in Q1 2019 and bottomed at -$95000.0 in Q4 2022.
- The 5-year median for Capital Expenditures is $47500.0 (2022), against an average of $49667.8.
- The widest annual swing landed in 2019, when Capital Expenditures jumped 1256.15%; it then sank 963.64% in 2022.
- A 5-year view of Capital Expenditures shows it stood at $2.0 in 2019, then jumped by 3149900.0% to $63000.0 in 2020, then slumped by 82.54% to $11000.0 in 2021, then tumbled by 963.64% to -$95000.0 in 2022, then surged by 266.32% to $158000.0 in 2023.
- The last three Capital Expenditures figures came in at $158000.0 (Q1 2023), -$95000.0 (Q4 2022), and $39000.0 (Q3 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 158,000.00 |
| Mar 31, 2023 | 158,000.00 |
| Dec 31, 2022 | -95,000.00 |
| Dec 31, 2022 | -95,000.00 |
| Sep 30, 2022 | 39,000.00 |
| Sep 30, 2022 | 39,000.00 |
| Jun 30, 2022 | 56,000.00 |
| Jun 30, 2022 | 56,000.00 |
| Dec 31, 2021 | 11,000.00 |
| Dec 31, 2021 | 11,000.00 |
| Sep 30, 2021 | 81,000.00 |
| Sep 30, 2021 | 81,000.00 |
| Mar 31, 2021 | 21,000.00 |
| Mar 31, 2021 | 21,000.00 |
| Sep 30, 2020 | 63,000.00 |
| Sep 30, 2020 | 63,000.00 |
| Dec 31, 2019 | 2.00 |
| Dec 31, 2019 | 2.00 |
| Sep 30, 2019 | 5,085.00 |
| Sep 30, 2019 | 5,085.00 |
| Jun 30, 2019 | 90,957.00 |
| Jun 30, 2019 | 90,957.00 |
| Mar 31, 2019 | 165,969.00 |
| Mar 31, 2019 | 165,969.00 |
| Dec 31, 2018 | 499,358.00 |
| Dec 31, 2018 | 499,358.00 |
| Sep 30, 2018 | 39,126.00 |
| Sep 30, 2018 | 39,126.00 |
| Jun 30, 2018 | 6,707.00 |
| Jun 30, 2018 | 6,707.00 |
| Mar 31, 2018 | 19,224.00 |
| Mar 31, 2018 | 19,224.00 |
| Dec 31, 2017 | 15,335.00 |
| Dec 31, 2017 | 15,335.00 |
| Sep 30, 2017 | 6,189.00 |
| Sep 30, 2017 | 6,189.00 |
| Mar 31, 2017 | 1,801.00 |
| Mar 31, 2017 | 1,801.00 |
| Dec 31, 2016 | 9,237.00 |
| Dec 31, 2016 | 9,237.00 |
| Sep 30, 2016 | 6,489.00 |
| Sep 30, 2016 | 6,489.00 |
| Jun 30, 2016 | 10,259.00 |
| Jun 30, 2016 | 10,259.00 |
| Mar 31, 2016 | 8,898.00 |
| Mar 31, 2016 | 8,898.00 |